Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q3 FY25 Earnings Presentation
28 slides from Dishman Carbogen Amcis's earnings presentation, Feb 12, 2025
Slide 1: Cover letter to stock exchanges
12th February, 2025 To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, “Exchange Plaza”, C-1, Block G, Mumbai – 400 001. Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref.: Scrip Code
Slide 2: Investor Presentation Quarter ended December 31st, 2024
Investor Presentation Quarter ended December 31 st , 2024
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward- looking statements, which may include statements relating to future results o
Slide 4: Dishman in a Nutshell
DISHMAN IN A NUTSHELL 4 decades 2,200+ Team Strength 25 28 Committed Members Embracing of Long-Standing Track Record in our Culture of Innovation & Sustainability CRAMS Dedicated Team/Scientist Working Multi-Purpose MANUFACTURING RESEARCH & DEVELOPMENT APIs in R&D - 950+ FACILITIES Globally and HIPO
Slide 5: Past Performance at a Glance
PAST PERFORMANCE AT A GLANCE Revenue from Operations (₹ mn) EBITDA and EBITDA % Cash Profit (₹ mn) 26,158 EBITDA EBITDA % 4,087 24,129 21,407 3,374 3,260 20,436 19,120 4,976 3,039 3,902 4,142 4,085 2,538 2,744 18.2% 17.2% 15.6% 24.3% 14.3% FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22^ FY23^ FY24^ FY20 FY
Slide 6: Agenda
AGENDA 01 Quarter Highlights 02 Company Overview 03 Industry Overview
Slide 7: Quarter Highlights
QUARTER HIGHLIGHTS
Slide 8: Q3 FY25 Result Highlights
Q3 FY25 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN 6,511 6,823 1,407 20.6% 6.5% 426 Q3FY24 Q3FY25 Q3FY24^ Q3FY25^ CASH PAT (₹ mn) & CASH EPS (₹) 5.9 903 1.8 278 Q3FY24 Q3FY25 Cash PAT = Adjusted PAT + (Depreciation - additional goodwill amortization) Adjusted PAT = Adjusted P
Slide 9: 9M FY25 Result Highlights
9M FY25 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN 19,611 19,952 3,185 2,323 16.0% 11.8% 9MFY24 9MFY25 9MFY24^ 9MFY25^ CASH PAT (₹ mn) & CASH EPS (₹) 2,119 1,648 13.5 10.5 9MFY24 9MFY25 Cash PAT = Adjusted PAT + (Depreciation - additional goodwill amortization) Adjusted PAT =
Slide 10: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (₹ mn) Q3 FY25 Q3 FY24 YoY % 9M FY25 9M FY24 YoY % Income from Operations (Net) 6,823.4 6,510.9 4.8% 19,951.6 19,610.6 1.7% COGS 988.3 1,181.2 -16.3% 3,557.4 4,157.8 -14.4% Employee Expenses 3320.8 3,092.0 7.4% 9,686.3 8,873.9 9.2% Other Expenses 1,107.7 1,812.
Slide 11: Revenue Breakup Analysis
REVENUE BREAKUP ANALYSIS Revenue (₹ mn) Q3 FY25 Q3 FY24 YoY % 9M FY25 9M FY24 YoY % CARBOGEN AMCIS - Contract Research & 5,124.0 5,058.1 1.3% 15,144.4 15,039.5 0.7% Manufacturing Services1 CARBOGEN AMCIS- Cholesterol & Vit D 506.5 610.0 -20.4% 1,843.2 2,409.3 -23.5% Analogues2 DCAL India - NCE APIs
Slide 12: Revenue Break-up
REVENUE BREAK-UP Total Operating Revenue – Q3 FY25 CARBOGEN AMCIS - Contract Research & Manufacturing Services 11.4% 6.1% 7.4% CARBOGEN AMCIS - Cholesterol & Vit D Analogues DCAL India - NCE APIs & Intermediates 75.1% DCAL India - Quats & Generics 11
Slide 13: Margin Analysis
MARGIN ANALYSIS Adjusted EBITDA Margin %* Q3 FY25 Q3 FY24 9M FY25 9M FY24 CARBOGEN AMCIS - Contract Research & Manufacturing 23.7% 19.9% 18.0% 18.3% Services2 CARBOGEN AMCIS- Cholesterol & Vit D Analogues3 14.6% 16.6% 9.1% 15.0% DCAL India - NCE APIs & Intermediates1 11.0% 11.3% 11.5% - DCAL India -
Slide 14: Q3 & 9M FY25 Result Highlights
Q3 & 9M FY25 RESULT HIGHLIGHTS Net Revenue at Rs 6,823.4 mn in Q3 FY25 up by 4.8% YoY mainly due to increase in revenue at DCAL. CAARBOGEN AMCIS – CRAMS revenue increased by 1.3% YoY in Q3 FY25 primarily due to increase in sales of commercial products out of Switzerland. CARBOGEN AMCIS BV– Cholester
Slide 15: ADC & Bioconjugation Business
ADC & BICONJUGATION BUSINESS
Slide 16: ADC & Bioconjugation Integrated Business at CGAM / DCAL
ADC & Bioconjugation Integrated Business at CGAM / DCAL BDS Bulk Drug Substance GMP-manufacture BIO-CONJUGATION Services • Process Transfer/development/validation • QC&A Transfer/development/validation • DL/BDS/DP GMP-manufacturing • ICH Stability DL • End-to-end RA support DP Drug Linker* Drug Prod
Slide 17: ADC & Bioconjugation Business Update
ADC & Bioconjugation Business Update ADC & Bioconjugation Integrated Business at CGAM / DCAL Dozens of quotes for multiple different clients > 30% success rate so far Client base is from small biotech up to the biggest pharma companies Successful collaboration agreements with start-up companies More
Slide 18: Company Overview
COMPANY OVERVIEW
Slide 19: About Us
ABOUT US Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical co
Slide 20: Key Strengths
KEY STRENGTHS Preferred global outsourcing Upfront investment of more partner with capabilities across the than ₹10,000 mn in large entire CRAMS value chain scale multi-purpose manufacturing capacities Strong chemistry skills The HIPO facility at Bavla, India is the largest HIPO facility in Asia. Di
Slide 21: Manufacturing Facilities
ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: Superior Chemistry Skills & Capabilities USFDA, MEB, SWISS MEDIC, ANSM, WHO, MFDS, PMDA 28 dedicated R&D labs with multiple shift R&D CARBOGEN AMCIS BV., Veenendaal, The CARBOGEN AMCIS operations, including HIPO labs (Sha
Slide 22: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER CLOSE PROXIMITY LARGE SCALE INTEGRATED ACROSS THE STRONG CHEMISTRY TO CLIENTS WITH MANUFACTURING VALUE CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 23: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER CARBOGEN AMCIS (CA) STRONG RESEARCH CAPABILITIES ▪ Focus is on supporting the development process from bench to market ▪ Process research and development to the supply of APIs for preclinical studies, clinical trials and commercial use DISHMAN INDIA STRONG MANUFACTURING CAPAB
Slide 24: Cutting Edge HIPO Capabilities
CUTTING EDGE HIPO CAPABILITIES The HIPO facility at Bavla, India, is one of the kind facility in the world and the largest facility in Asia. The facility has a sound mix of Kilo lab and full- scale manufacturing units to cater to both small volume and large volume orders. State of the art containmen
Slide 25: Industry Overview
INDUSTRY OVERVIEW
Slide 26: Expected Global Spending by Therapy Areas in 2028
EXPECTED GLOBAL SPENDING BY THERAPY AREAS IN 2028 Oncology & Obesity expected to lead growth 5-Yr CAGR 2024-2028 Oncology 440 14-17% Immunology 192 2-5% Top 20 Therapy Areas (US$ bn) - 2028 Diabetes 184 3-6% Cardiovascular 126 2-5% CNS 103 6-9% Respiratory 99 3-6% Mental health 81 9-12% Infectious d
Slide 27: Specialty: Market Share & Growth
SPECIALTY: MARKET SHARE & GROWTH Specialty medicines will represent about 43% of global spending in 2028 and 55% of total spending in developed markets 55% 50% 43% 43% 40% 41% 35% 36% 31% 29% 23% 24% 13% 13% 10% 8% 2013 2018 2023 2028 Pharmerging Other Developed Global 10 Developed Source: IQVIA Ins
Slide 28: For Further Queries
FOR FURTHER QUERIES Mr. Harshil Dalal Dishman Carbogen Amcis Ltd Global CFO Dishman Corporate House Email: harshil.dalal@dishmangroup.com Iscon-Bopal Road, Ambli Ahmedabad - 380058 Gujarat, Mr. Binay Sarda India Ernst & Young LLP www.imdcal.com P: +91 9920893764 Email: binay.sarda@in.ey.com
Dishman Carbogen Amcis — Q3 FY25 Earnings Presentation on 6ix